Skip to content

PTSD: all studies

Page 8 of 211: studies 71 to 80 of 2,103, newest first. Back to the PTSD overview

Research

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

medRxiv Preprint Server March 27, 2026 Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey et al. preprint

3,4-methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD), generating considerable enthusiasm in the field. However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release,...

Impact of subanesthetic ketamine delivered via AmyloLipid nanovesicle (ALN)-based intranasal system on biobehavioral responses in an animal model of PTSD

Translational Psychiatry March 25, 2026 Gal Levi, Amnon Sintov, Joseph Zohar et al.

Ketamine holds promise for the treatment of post-traumatic stress disorder (PTSD), but challenges remain in delivery and sustained effects. This controlled study evaluates a novel intranasal formulation, employing AmyloLipid nanovesicles (ALN) to enhance ketamine’s therapeutic efficacy in a predator-scent stress (PSS) rat model of PTSD. A total of 130 rats underwent PSS or sham-PSS exposure,...

Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder

bioRxiv (Cold Spring Harbor Laboratory) March 24, 2026 Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al. 1 citation preprint

Abstract Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions of veterans. A recent observational study in 30 veterans showed that a single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD up to twelve months later. Although a prior study demonstrated that ibogaine transiently alters electroencephalography (EEG) power in...

DOI: 10.64898/2026.03.20.713241 (opens in new tab) Full text (opens in new tab) Electroencephalography Neuroimaging Biomarker Nerve net +2

A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies.

European Journal of Psychotraumatology March 19, 2026 Philip Gerrans, Hugh McGovern, Jakob Hohwy et al.

Background: Complex post-traumatic stress disorder (C-PTSD) is a trauma-related condition characterized by pervasive disturbances in affect regulation, self-concept, and interpersonal functioning that extend beyond the symptom profile of post-traumatic stress disorder (PTSD). While neurobiological studies have implicated limbic, salience, and prefrontal systems in C-PTSD, mechanistic accounts...

DOI: 10.1080/20008066.2026.2631358 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine 4-metilendioximetanfetamina C-PTSD MDMA-Assisted Psychotherapy +5

Effects of Prazosin and Other Alpha-1 Adrenergic Antagonist Drugs on Nightmares and Sleep Disturbances in Posttraumatic Stress Disorder

Journal of Clinical Psychopharmacology March 12, 2026 Olga Y. Ponomareva, Sean R. Stetson, Bruce Meltzer et al.

PURPOSE/BACKGROUND: Chronic insomnia causes malaise and is associated with depression, irritability, cognitive impairment, impaired alertness, and substance abuse. Individuals with posttraumatic stress disorder (PTSD) often have both inadequate and fragmented sleep, putting them at elevated risk for these consequences. Sleep abnormalities in patients with PTSD include frequent trauma-related...

DOI: 10.1097/jcp.0000000000002164 (opens in new tab) Prazosin Posttraumatic stress Adrenergic antagonist Sleep system call +3

State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder

Journal of Traumatic Stress March 12, 2026 Leslie A. Morland, Barbara O Rothbaum, Lauren M. Sippel et al. 2 citations

There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine...

DOI: 10.1002/jts.70060 (opens in new tab) Posttraumatic stress Cognition Cognitive behavioral therapy Leverage statistics +9

Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes

European Neuropsychopharmacology March 12, 2026 Natalia E. Fares-Otero, Yuki Furukawa, Marit Sijbrandij et al.

Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to estimate the efficacy of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) compared with control on clinical and functional outcomes in PTSD. A PRISMA-compliant search (PROSPEROCRD42022353261) up to August 14, 2025, covered nine databases...

DOI: 10.1016/j.euroneuro.2026.112802 (opens in new tab) Dissociative Posttraumatic stress Clinical trial Cognition +12

Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review

American Journal of Health-System Pharmacy March 4, 2026 Jennifer E. Thomas, Anna Dellarole, Robin J Jacobs

MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for...

DOI: 10.1093/ajhp/zxag062 (opens in new tab) MDMA Psilocybin Expectancy theory Posttraumatic stress +5

Flashbacks Through Time: Historical Development and Current Use of the Term "Flashback" in Psychedelic and Post-Traumatic Stress Disorder Research.

Psychiatric Research and Clinical Practice March 3, 2026 Ricarda Evens

In psychiatry, the term flashback is widely recognized in relation to post-traumatic stress disorder (PTSD) as well as in the characterization of post-psychedelic experiences. Although it is now most commonly associated with PTSD, the term was originally introduced in the context of psychedelics. While it broadly denotes specific forms of re-experiencing in both fields, its precise meaning...

The Endocannabinoid System in PTSD: Molecular Targets for Modulating Fear and Anxiety.

Pharmacopsychiatry March 2026 Stanley Lyndon

Fear and anxiety perform essential protective roles, yet when they become dysregulated, they can trap trauma survivors in persistent hypervigilance and distress. Post-traumatic stress disorder (PTSD) manifests as intrusive memories, avoidance, and heightened arousal long after the precipitating event. Although current pharmacotherapies - including selective serotonin reuptake inhibitors,...